Last updated on February 2018

Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST)

Brief description of study

Patients undergoing percutaneous coronary intervention with a residual high platelet reactivity despite oral clopidogrel are at increased risk of ischaemic complications. The strategies to overcome the issue consist of switch to a more potent antiplatelet medications including prasugrel or ticagrelor. Economic constrains of many countries still do not allow wide reimbursement of newer antiplatelet agents. Therefore a strategy to personalise treatment according to genotype and phenotype characteristics of the patient may provide an attractive solution combining high clinical efficacy with low budget impact.

Clinical Study Identifier: NCT01930773

Contact Investigators or Research Sites near you

Start Over

Lukasz Koltowski, MD, PhD

Heart Center Balatonf red
Balatonfüred, Hungary
  Connect »

Lukasz Koltowski, MD

1st Department of Cardiology, Medical University of Warsaw
Warsaw, Poland
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.